Lakefront Biotherapeutics NV (NASDAQ:LKFT) — Stock Price
Lakefront Biotherapeutics NV (NASDAQ:LKFT) is currently trading at $28.80 USD, up 1.87% today. Over the past 52 weeks, shares have ranged between $26.08 and $30.81. This page tracks Lakefront Biotherapeutics NV's live share price on the NASDAQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. To see how efficiently this company converts equity into cash flow, see Lakefront Biotherapeutics NV (LKFT) cash flow conversion.
Lakefront Biotherapeutics NV (LKFT) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Lakefront Biotherapeutics NV's daily closing share price and trading volume on the NASDAQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
Lakefront Biotherapeutics NV Income Statement — Revenue, Profit & Earnings by Year
Lakefront Biotherapeutics NV's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total Revenue | $1.11 Billion | $275.65 Million | $239.72 Million | $241.25 Million |
| Cost of Revenue | $29.74 Million | $34.86 Million | $0.00 | $0.00 |
| Gross Profit | $1.08 Billion | $240.79 Million | $239.72 Million | $241.25 Million |
| Research & Development | $459.42 Million | $335.46 Million | $241.29 Million | $269.80 Million |
| SG&A | $110.57 Million | $96.88 Million | $94.25 Million | $103.31 Million |
| Total Operating Expenses | $581.12 Million | $463.99 Million | $327.99 Million | $372.31 Million |
| Operating Income | $501.39 Million | $-188.34 Million | $-88.26 Million | $-131.06 Million |
| EBITDA | $358.96 Million | — | — | — |
| EBIT | $303.09 Million | — | — | — |
| Interest Expense | $2.22 Million | $911.00K | $1.77 Million | $9.15 Million |
| Income Before Tax | $300.87 Million | $-3.08 Million | $5.62 Million | $-70.85 Million |
| Income Tax Expense | $-18.62 Million | — | — | — |
| Net Income | $320.88 Million | $74.08 Million | $211.70 Million | $-217.99 Million |
Lakefront Biotherapeutics NV Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Lakefront Biotherapeutics NV's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total Assets | $3.41 Billion | $4.14 Billion | $4.36 Billion | $4.73 Billion |
| Total Current Assets | $3.08 Billion | $3.34 Billion | $3.86 Billion | $4.24 Billion |
| Cash & Equivalents | — | — | — | — |
| Short-term Investments | $2.91 Billion | $3.05 Billion | $3.52 Billion | $3.59 Billion |
| Net Receivables | $53.20 Million | $32.47 Million | $17.49 Million | $28.19 Million |
| Inventory | $22.49 Million | $51.19 Million | $73.98 Million | $52.92 Million |
| Property, Plant & Equipment | — | — | — | — |
| Goodwill | $0.00 | $70.01 Million | $69.56 Million | $69.81 Million |
| Total Liabilities | $170.65 Million | $1.24 Billion | $1.56 Billion | $2.21 Billion |
| Total Current Liabilities | $152.86 Million | $335.08 Million | $428.22 Million | $522.54 Million |
| Long-term Debt | — | — | — | — |
| Net Debt | $-80.95 Million | — | — | — |
| Total Stockholder Equity | $3.24 Billion | $2.90 Billion | $2.80 Billion | $2.53 Billion |
| Retained Earnings | $210.58 Million | $-134.31 Million | $-228.27 Million | $-496.69 Million |
Lakefront Biotherapeutics NV Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Lakefront Biotherapeutics NV generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating Cash Flow | $-257.46 Million | $-320.03 Million | $-405.97 Million | $-500.54 Million |
| Capital Expenditures | $13.86 Million | $82.11 Million | $19.27 Million | $36.95 Million |
| Free Cash Flow | $-271.31 Million | $-402.14 Million | $-425.24 Million | $-537.49 Million |
| Investing Cash Flow | $288.81 Million | — | — | — |
| Financing Cash Flow | $-3.27 Million | $-4.92 Million | $-5.00 Million | $-1.49 Million |
| Dividends Paid | — | — | — | — |
| Stock-Based Compensation | $24.00 Million | $19.89 Million | $56.72 Million | $88.51 Million |
| Depreciation | $55.88 Million | $45.50 Million | $43.64 Million | $65.57 Million |
| Change in Cash | $23.63 Million | $-104.35 Million | $-339.79 Million | $-1.75 Billion |
Lakefront Biotherapeutics NV Earnings History — EPS Actual vs. Analyst Estimates
Track Lakefront Biotherapeutics NV's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Aug 10, 2026 | — | -11.50 | — |
| May 07, 2026 | 0.21 | -0.97 | +121.65% |
| Mar 26, 2026 | 12.27 | -0.07 | +17628.57% |
| Nov 05, 2025 | -0.18 | -0.28 | +35.71% |
| Jul 23, 2025 | -0.93 | -0.13 | -615.38% |
| Apr 23, 2025 | 0.97 | -0.18 | +638.89% |
| Feb 13, 2025 | 0.41 | — | — |
| Oct 30, 2024 | -0.74 | -0.12 | -516.67% |